Wednesday, April 24, 2024
HomeRecent ArticlesOnCusp Therapeutics Raises Oversubscribed $100 Mn Series A Financing

[Funding alert]OnCusp Therapeutics Raises Oversubscribed $100 Mn Series A Financing

OnCusp Therapeutics, Inc., a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, today announced an oversubscribed $100 million Series A financing round.

OnCusp Therapeutics, Inc., a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide, announced an oversubscribed $100 million Series A financing round.

Read also – Elevance Health to Acquire Paragon Healthcare

The round was co-led by Novo Holdings, OrbiMed, and F-Prime Capital, alongside Sofinnova Investments, Catalio Capital Management, Marshall Wace, Forge Life Science Partners, Blackbird BioVentures, CJNV BioVenture and others, as well as BioTrack Capital, a co-lead for the Seed Round. OnCusp Therapeutics has raised $139 million since its establishment in April 2021. The proceeds from this financing will be used to advance CUSP06, an ADC targeting CDH6, toward clinical proof-of-concept. Additionally, the capital will aid in expanding the OnCusp portfolio and team.

Read also – [Funding alert]Banner Ridge Partners Raises $2.15 Billion in Oversubscribed Secondary Fund V

“We are grateful to have the trust and support from some of the most prominent global biotech investors,” said Dr. Bing Yuan, Co-Founder and CEO of OnCusp Therapeutics. “I am also thankful to the OnCusp team for their commitment and excellent work. We hold a strong conviction to develop innovative oncology therapies for patients. This significant Series A financing enables OnCusp to accelerate the development of CUSP06 and other game-changing therapeutics in our fight against cancer.”

Read also – TCG Crossover Closes TCGX Fund II with $1B in capital

As part of the financing, OnCusp Therapeutics will appoint Dr. Karen Hong, Partner in the Venture Investments team at Novo Holdings US, Inc., a wholly owned subsidiary of Novo Holdings; Diyong Xu, Principal at OrbiMed; and Dr. Chong Xu, Partner at F-Prime Capital, to the company’s Board of Directors.

Read also – [Funding alert]Varlo Sports Raises Undisclosed Amount in Seed Funding

“We are thrilled to have co-led this round. The remarkable progress that the company has made in such a short time is a testament to its highly efficient business model and the team’s exceptional execution capabilities,” said Dr. Karen Hong. “We share OnCusp’s mission in bringing oncology innovations to life and are committed to supporting the company’s continued growth and success.”

Read also – [Funding alert]HI-Bio Raises $95 Mn Series B Funding to Advance Targeted Therapies

“ADCs have become one of the most promising modalities for treating cancer, and CDH6 is emerging as a winning ADC target. We believe CUSP06 is well positioned to unlock the full potential of this target, both in high and low CDH6 expressing tumors,” said Diyong Xu. “We also look forward to OnCusp expanding its portfolio to fully leverage its translational and clinical development expertise.”

Read also – [Funding alert]Perplexity Raises $73.6M Series B Funding Round

About OnCusp Therapeutics

OnCusp Therapeutics, Inc., headquartered in New York City, is a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide. OnCusp was co-founded by Dr. Bing Yuan, Dr. Eric Slosberg, and Dr. Andy Fu, and has built a strong team of accomplished veterans with proven track records in building startup biotechs, leading successful preclinical and clinical programs, and creating value through global partnerships. The company is committed to accelerating the advancement of globally competitive oncology assets for patients.

Read also – [Funding alert]Arbital Health Acquires Santa Barbara Actuaries and Closes  $10M Series A Funding

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular